Mergers & Acquisitions (M&A)

Photo
28.08.2025 • NewsStrategy

IMCD to Acquire Tillmanns

IMCD, a partner for the distribution and formulation of speciality chemicals and ingredients, has signed an agreement to acquire 100% of the shares in Tillmanns.

Photo
21.07.2025 • News

Harke Acquires Swedish Vendico

Harke Group, based in Mülheim an der Ruhr, Germany, acquired the Swedish Vendico Group, comprising Vendico Chemical, Inventicon, and Omni International.

Photo
08.07.2025 • News

Bio-Rad Acquires Stilla Technologies

Bio-Rad Laboratories, a life science research and clinical diagnostics company, has completed the acquisition of Stilla Technologies, a developer of digital PCR (dPCR) systems.

Photo
02.07.2025 • News

BASF Completes Acquisition of DOMO Chemicals' Shares in Alsachimie JV

BASF has acquired DOMO Chemicals' 49% stake in the Alsachimie joint venture and is now the sole owner of the production company for essential precursors of polyamide (PA) 6.6, including KA oil, adipic acid and hexamethylenediamine adipate (AH salt) in Chalampé, France. The parties have agreed not to disclose financial details of the transaction.

Photo
02.06.2025 • News

BASF to Acquire Shares in Alsachimie

BASF and DOMO Chemicals have signed an agreement giving BASF the right to acquire DOMO Chemicals' 49% stake in the Alsachimie joint venture, in which BASF currently holds 51%.

Photo
03.04.2025 • News

HAS Acquires Cerbios-Pharma

HAS Healthcare Advanced Synthesis (HAS) recently announced the planned acquisition of Cerbios-Pharma (Cerbios), a globally recognized manufacturer of chemical and biological APIs, including antibody-drug conjugates (ADCs).

Photo
02.04.2025 • News

Ineos Energy Acquires Oil & Gas Assets from CNOOC

The completion of the deal marks the third major investment by Ineos Energy in the USA in the past three years. It increases Ineos' capital spending on energy assets in the USA to above $3 billion.

Photo
11.03.2025 • News

Sun Pharma to Acquire Checkpoint Therapeutics

Indian generic drug maker Sun Pharma agreed to acquire US immunotherapy and targeted oncology company Checkpoint Therapeutics for an upfront value of $355 million. The transaction is expected to be completed in the second quarter of 2025 and is subject to customary closing conditions.

1998 more articles

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.